Ticagre%25252520%25252528ticagrelor%25252529

# Ticagrelor ## Overview Ticagrelor is a reversible, non-thienopyridine P2Y12 platelet inhibitor that directly binds to the P2Y12 receptor. Unlike clopidogrel, it does not require metabolic activation. ## Primary Indications * Acute coronary syndrome (ACS): Treatment of unstable angina, NSTEMI, and STEMI to reduce the rate of cardiovascular death, MI, and stroke. * History of MI: Secondary prevention in patients at high risk of a future thrombotic event. * Coronary artery disease (off-label/investigational): Monotherapy or combination therapy for select high-risk patients. ## Adult Dosing * **Loading Dose:** 180 mg PO once. * **Maintenance Dose:** 90 mg PO twice daily. * **Post-12 Months (High-risk patients):** May reduce to 60 mg PO twice daily. * **ASA Concomitance:** Maintenance aspirin dose should generally not exceed 100 mg daily; higher doses reduce efficacy. ## Pediatric Dosing Safety and efficacy have not been established in pediatric patients under 18 years of age. Dosing is not indicated. ## Dose Adjustments * **Renal Impairment:** No dose adjustment required. Not dialyzable. * **Hepatic Impairment:** Mild impairment (Child-Pugh A): No adjustment. Severe impairment: Avoid use; not studied and potential for increased bleeding. ## Contraindications * Active pathological bleeding (e.g., peptic ulcer, intracranial hemorrhage). * History of intracranial hemorrhage. * Severe hepatic impairment. * Known hypersensitivity to ticagrelor. ## Adverse Effects * **Bleeding:** Major and minor bleeding (epistaxis, hematomas, GI bleed). * **Dyspnea:** Very common (10–14%), typically self-limiting. * **Bradyarrhythmia:** Higher risk of ventricular pauses, typically within the first week of therapy. * **Uric Acid:** Potential for asymptomatic elevations (rarely gout). ## Key Drug Interactions * **CYP3A4 Inhibitors (e.g., Ketoconazole, Clarithromycin, Ritonavir):** Strong inhibitors significantly increase ticagrelor levels; avoid concurrent use. * **CYP3A4 Inducers (e.g., Rifampin, Phenytoin):** Reduce ticagrelor efficacy; avoid concurrent use. * **Simvastatin/Lovastatin:** Increased risk of myopathy; limit doses of these statins to 40 mg daily when used with ticagrelor. * **Digoxin:** Ticagrelor may increase digoxin levels; monitor serum concentrations. ## Monitoring * **Clinical:** Observe for signs of bleeding (melena, hematuria, hemoptysis). * **Labs:** Periodic hemoglobin/hematocrit if bleeding is suspected. * **ECG:** Monitor for bradycardia if patient has preexisting conduction defects (e.g., 2nd or 3rd-degree AV block). ## Clinical Pearls * **Reversibility:** Unlike clopidogrel or prasugrel, the binding is reversible. Platelet function typically returns to normal in 3–5 days following discontinuation. * **Transitioning:** If switching from clopidogrel, administer loading dose at the time of the next scheduled dose. * **Surgery:** If elective surgery is required where antiplatelet therapy must be withheld, discontinue ticagrelor at least 5 days prior to the procedure to minimize bleeding risk. * **Dyspnea Management:** If dyspnea is intolerable, investigate other cardiac/pulmonary causes; if none, consider switching P2Y12 inhibitor. *** **Disclaimer:** This information is for educational purposes and does not substitute for professional medical judgment. Always verify current prescribing information, institutional protocols, and patient-specific factors before initiating therapy.